Why EyePoint’s 67% Collapse Makes Its Second Phase 3 Trial Existential
$EyePoint(EYPT)$’s first pivotal trial of DURAVYU did not merely disappoint investors; it undermined the central evidence needed to establish that the sustained-release eye implant can preserve vision as effectively as the current standard treatment.
EyePoint announced on August 17 that LUGANO, the first of two Phase 3 studies in wet age-related macular degeneration, failed its primary endpoint. DURAVYU reduced the need for supplemental injections by 42%, but did not demonstrate statistical non-inferiority to Regeneron’s Eylea in the average change in best-corrected visual acuity at week 52.
Nine of 211 DURAVYU-treated patients experienced vision loss that investigators considered unrelated to the disease, versus none in the Eylea group. EyePoint’s investor-relations announcement contains the company’s topline disclosure, while Reuters’ August 17 report explains the efficacy and safety comparisons.
The bullish case has narrowed but has not disappeared. A long-acting implant that meaningfully reduces injection frequency would address a genuine burden for patients and clinics. Management argues that unusual vision-loss cases distorted LUGANO and that an ad-hoc analysis excluding those patients supported non-inferiority. The second pivotal study, LUCIA, uses a related design and could still produce cleaner data.
The bearish case is much stronger. Post-hoc exclusions are hypothesis-generating rather than a substitute for a prespecified primary endpoint. Even if the drug reduces treatment burden, physicians and regulators are unlikely to accept a possible vision trade-off without compelling evidence. EyePoint expects to pursue approval in the first half of 2027 if LUCIA succeeds, but a negative or ambiguous second study would leave the programme without the customary two positive pivotal trials.
EyePoint fell over 60% to $4.87 on approximately 52.3 million shares after trading between $3.52 and $15.29. That gap destroyed the previous chart structure. The $3.50–$4 area is now speculative support, while $6 followed by the $14.77 pre-announcement close becomes resistance. Technical levels are unusually unreliable because the next material move will depend on clinical and regulatory evidence.
The evidence leans bearish. DURAVYU’s convenience benefit is meaningful, but it does not compensate for failure on vision preservation and the unexplained imbalance in vision loss. The view would be invalidated by a clearly positive LUCIA result, a convincing explanation for the LUGANO outliers and explicit FDA agreement that the full evidence package can support approval. This is personal opinion for education and is not financial advice.
@Tiger_SG @Tiger_comments @TigerStars @TigerClub @CaptainTiger @Daily_Discussion
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The views expressed are personal opinions based on publicly available information and are subject to change without notice. Investors should conduct their own research and consider their financial situation, risk tolerance, and investment objectives before making any investment decisions. I do not guarantee the accuracy or completeness of the information presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
